DEPAKINE 200/MG TAB 40/TAB

Indications

Approved Uses

Epilepsy (generalized and focal/partial seizures, including absence) and treatment of manic episodes in bipolar disorder.

Off-Label Uses

Migraine prophylaxis (commonly off-label depending on jurisdiction/product labeling); other proposed uses (e.g., neuropathic pain, behavioral/aggression) have limited/variable evidence and are not standard guideline indications.

Dosage & Administration

Dosing by Condition

Epilepsy (adults): start ~10-15 mg/kg/day (or ~600 mg/day) in divided doses and increase by ~5-10 mg/kg/week (or ~200 mg increments) to usual maintenance ~1000-2000 mg/day; max commonly 2500 mg/day (or up to 60 mg/kg/day in some references). Bipolar mania (adults): start ~750 mg/day (or ~20 mg/kg/day) and titrate to effect; typical 1000-2000 mg/day. Migraine prophylaxis: not an approved indication for this product; if used (off-label), typical total daily doses are ~500-1000 mg/day.

Initial Dose

600mg/day in 2-3 divided doses for epilepsy in adults

Maintenance Dose

1000-2000mg/day in 2-3 divided doses (adults); target serum level 50-100 mcg/mL

Maximum Dose

Maximum: 60 mg/kg/day (commonly cited absolute cap ~2500-3000 mg/day in adults depending on label/indication, but weight-based 60 mg/kg/day is the standard ceiling).

Children's Dosage

Children over 1 month: Initial 10-15mg/kg/day in 2-3 divided doses; increase by 5-10mg/kg/week; maintenance 20-30mg/kg/day; max 60mg/kg/day. Use with extreme caution in children under 2 years due to high risk of fatal hepatotoxicity

Dose Adjustment Notes

Titrate gradually to clinical response/tolerability; contraindicated in significant hepatic disease; in renal impairment, total levels may be misleading due to reduced protein binding-consider monitoring free valproate and clinical response; in elderly, start lower and titrate slowly; pediatric dosing is weight-based.

How to Take

Swallow the gastro-resistant tablets whole with water; do not crush or chew; take with or after food if gastrointestinal upset occurs; dose is usually given in 2-3 divided doses daily (unless using a modified-release product).

Side Effects

Common Side Effects

Nausea, vomiting, diarrhea, abdominal pain, weight gain, tremor, somnolence, dizziness, headache, alopecia (hair loss), thrombocytopenia, increased appetite

Side Effect Frequency

Very common/common: GI upset (nausea ± vomiting), tremor, somnolence/dizziness, weight gain/increased appetite, alopecia, and thrombocytopenia. Rare but serious: hepatotoxicity, pancreatitis, severe cutaneous adverse reactions (e.g., SJS/TEN/DRESS), hyperammonemic encephalopathy, and suicidal ideation.

Safety & Warnings

Contraindications

Contraindicated in: active hepatic disease/significant hepatic dysfunction; known urea cycle disorders; known/suspected POLG-related mitochondrial disorders; porphyria; hypersensitivity to valproate/valproic acid/valproate sodium. Also contraindicated for migraine prophylaxis in pregnancy (and generally avoided/strictly restricted in pregnancy and in women of childbearing potential unless no suitable alternative under a pregnancy-prevention program).

Warnings & Precautions

Key warnings/precautions: monitor for hepatotoxicity (baseline and during first 6 months; highest risk in young children/metabolic disease), pancreatitis (stop if suspected), teratogenicity-avoid in pregnancy when possible and enforce pregnancy-prevention measures in women of childbearing potential, hyperammonemia/encephalopathy (especially with urea-cycle disorders or with topiramate), hematologic effects (platelets/coagulation), suicidality monitoring, weight gain/metabolic effects, and avoid abrupt withdrawal.

Age Restriction

No absolute minimum age, but avoid if possible in children <2 years; if used, only with specialist oversight due to markedly higher risk of fatal hepatotoxicity-contraindicated in known/suspected POLG-related mitochondrial disorders (e.g., Alpers-Huttenlocher), and in urea cycle disorders.

Driving Warning

May Cause Drowsiness

Drug Interactions

Drug Interactions

Key clinically significant interactions: carbapenems (markedly lower valproate levels-avoid); lamotrigine (valproate increases lamotrigine exposure-higher rash/SJS risk; use lower lamotrigine doses); enzyme-inducing ASMs (phenytoin/carbamazepine/phenobarbital) and valproate (bidirectional level changes); topiramate (hyperammonemia/encephalopathy risk); warfarin/other anticoagulants (increased bleeding via protein-binding/platelet effects-monitor INR/bleeding); aspirin/salicylates (increase free valproate and bleeding risk-avoid high-dose); rifampicin (may reduce valproate levels).

Interaction Severity

MAJOR: Carbapenems (markedly lower valproate concentrations → loss of seizure control); lamotrigine (valproate increases lamotrigine exposure → serious rash/SJS risk). MODERATE/CLINICALLY SIGNIFICANT: topiramate (hyperammonemia/encephalopathy risk), phenytoin/phenobarbital/carbamazepine (bidirectional level/toxicity changes), warfarin (increased anticoagulant effect/bleeding risk), aspirin/salicylates (protein-binding displacement and bleeding risk).

Food Interaction

May be taken with or without food; taking with/after food can reduce gastrointestinal adverse effects; food does not meaningfully reduce overall exposure for gastro-resistant tablets.

Special Populations

Pregnancy

Use only if other medications have failed to control symptoms or are otherwise unacceptable

Breastfeeding

Caution

Children

Children over 1 month: Initial 10-15mg/kg/day in 2-3 divided doses; increase by 5-10mg/kg/week; maintenance 20-30mg/kg/day; max 60mg/kg/day. Use with extreme caution in children under 2 years due to high risk of fatal hepatotoxicity

Elderly

Start at lower doses and titrate slowly; monitor closely for sedation, tremor, and falls; reduced protein binding and decreased clearance may increase free drug levels; monitor serum levels regularly

Liver Impairment

Contraindicated in active liver disease or significant hepatic impairment; do not initiate, and discontinue if significant hepatic dysfunction develops.

Storage & Patient Advice

Stopping the Medicine

Do not stop abruptly; taper gradually under medical supervision (unless a serious adverse reaction mandates immediate discontinuation).

Overdose

Overdose may cause CNS depression (somnolence to coma), respiratory depression, hypotension, metabolic acidosis, hyperammonemia, and other electrolyte abnormalities; management is urgent supportive care (airway/ventilation, hemodynamics), activated charcoal if appropriate, and consider hemodialysis in severe poisoning/high levels or clinical deterioration.

Patient Counseling

Swallow gastro-resistant tablets whole (do not crush/chew); take with/after food to reduce GI upset. Do not stop valproate suddenly without prescriber advice (risk of seizure relapse). Avoid alcohol and use caution with driving/machinery until effects are known (may cause somnolence/dizziness). Seek urgent care for symptoms of hepatotoxicity (jaundice, dark urine, severe abdominal pain, persistent vomiting, marked fatigue), pancreatitis (severe abdominal pain with nausea/vomiting), or unusual bruising/bleeding (thrombocytopenia/coagulopathy). Attend recommended monitoring (LFTs, CBC/platelets ± valproate level as clinically indicated). Women of childbearing potential: valproate is highly teratogenic-use effective contraception and discuss pregnancy plans/alternatives with the prescriber before conception; do not stop abruptly if pregnancy occurs-seek urgent specialist review.

Monitoring Requirements

Baseline and periodic liver function tests (especially during the first 6 months), complete blood count/platelets, and clinical monitoring for pancreatitis and hyperammonemic encephalopathy; consider serum valproate concentrations when indicated (e.g., lack of response, suspected toxicity, interactions, pregnancy), and monitor weight/metabolic effects.

Pharmacology

Mechanism of Action

Increases brain GABA availability (e.g., inhibition of GABA metabolism), blocks voltage-gated sodium channels, and reduces T-type calcium currents, decreasing neuronal excitability.

Duration of Effect

Approximately 8-12 hours per dose for gastro-resistant/immediate-release valproate; commonly requires 2-3 times daily dosing.

Half-Life

Approximately 9-16 hours in adults (can be shorter in children and longer in neonates; reduced with enzyme-inducing co-medications).

Bioavailability

High oral bioavailability (approximately 90-100%); absorption is delayed (not reduced) by gastro-resistant/enteric-coated formulation.

Excretion

Primarily renal excretion as metabolites (mainly glucuronide conjugates and other metabolites); only a small fraction is excreted unchanged in urine (typically <3%).

Protein Binding

High, concentration-dependent protein binding (about 80-95%); binding decreases at higher concentrations and in hypoalbuminemia.

Product Information

Available Dosage Forms

For Depakine/valproate products: gastro-resistant (enteric-coated) tablets; modified/extended-release tablets (e.g., Chrono in some markets); oral solution/syrup; intravenous formulation (valproate sodium).

Composition per Dose

Each gastro-resistant tablet: 200mg valproate sodium

Generic Availability

Yes

OTC Alternatives

No OTC alternative

Also Used For

Mood Stabilization, Migraine Prevention, Neuropathic Pain, Bipolar Disorder (Manic Episodes)

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.